How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process
In an op-ed, Jason Karlawish of the Perelman School of Medicine outlines the reliable process required to properly evaluate the effects of lecanemab, a new Alzheimer’s drug already approved by the FDA.
・ From STAT News